CAR-T细胞疗法市场规模、份额和成长分析（按产品类型、标靶、适应症、治疗方法、人口统计、给药方式和地区划分）—2026-2033年产业预测

全球 CAR T 细胞疗法市场规模预计在 2024 年达到 50 亿美元，从 2025 年的 69.1 亿美元增长到 2033 年的 920 亿美元，在预测期（2026-2033 年）内复合年增长率为 38.2%。

CAR-T细胞疗法市场正经历显着增长，这主要得益于其在骨髓恶性肿瘤治疗方面的巨大潜力、全球癌症发病率的上升以及对个性化治疗日益增长的需求。基因编辑技术的创新和大型製药公司的巨额投资，在有利的法规环境下，进一步推动了先进CAR-T细胞疗法的研发。已通过核准治疗方法的卓越疗效增强了相关人员的信任，并扩大了患者的治疗范围，尤其是在医疗体系发达的国家。然而，高昂的治疗费用、复杂的生产过程以及相关的不利事件等挑战限制了CAR-T细胞疗法的可及性和市场渗透率。此外，新兴经济体熟练专业人员的短缺和基础设施的不足，也阻碍了CAR-T细胞疗法治疗潜力的充分发挥。

全球CAR-T细胞疗法市场驱动因素

全球CAR-T细胞疗法市场预计将迎来显着成长，这主要归功于人们对个人化医疗日益增长的兴趣。随着越来越多的患者寻求个人化治疗方案，对CAR-T细胞疗法的需求预计将大幅增加。这种创新疗法的疗效可以透过个人化治疗方案得到提升，该方案能够更精准地匹配每位患者的个别特征。这种客製化不仅能够改善患者的治疗效果，也引起了医疗专业人员和机构的广泛关注。随着个人化医疗在治疗研发中持续发挥核心作用，CAR-T细胞疗法市场有望从这种对个人化治疗策略的关注中获益匪浅。

限制全球CAR-T细胞疗法市场的因素

全球CAR-T细胞疗法市场面临与该疗法创新相关的重大挑战。儘管进行了广泛的测试，但人们对潜在副作用和长期安全性的担忧仍然突出。这些不确定性可能会限制CAR-T细胞疗法在医疗服务提供者和患者中的广泛接受和应用。在市场相关人员权衡这些风险和利益之际，对全面接受这项突破性治疗方法的犹豫可能会阻碍其发展和融入标准治疗通讯协定，并有可能在不久的将来影响整个市场的发展。

全球CAR-T细胞疗法市场趋势

全球CAR-T细胞疗法市场的一大趋势是异体CAR-T细胞疗法的开发，这种疗法无需针对特定患者进行定制，并简化了生产流程。这项创新有望提高CAR-T细胞疗法的可近性和可负担性，从而扩大其市场吸引力。随着各公司致力于开发此类治疗方法，它们的目标不仅是改善患者疗效，还要在新兴市场中占据有利地位。这种策略转变可望创造成长机会，帮助企业拓展业务范围，同时满足不同患者群的需求，进而推动整个产业的成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球 CAR-T 细胞疗法市场规模：按产品和复合年增长率划分（2026-2033 年）

• 耶斯卡塔
• 凯姆里亚
• 碳水化合物
• 阿别隈
• Tekartas
• 布里安吉
• 其他产品

全球 CAR-T 细胞疗法市场规模：按目标和复合年增长率划分（2026-2033 年）

• CD19
• BCMA
• HER2
• 其他目标

全球 CAR-T 细胞疗法市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 多发性骨髓瘤
• B细胞淋巴瘤
• 急性淋巴性白血病
• 其他迹象

全球 CAR-T 细胞疗法市场规模：按治疗方法和复合年增长率划分（2026-2033 年）

• 单药治疗
• 联合治疗

全球 CAR-T 细胞疗法市场规模：按人口统计和复合年增长率划分（2026-2033 年）

• 成人
• 儿童

全球 CAR-T 细胞疗法市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 住院病人
• 门诊

全球 CAR-T 细胞疗法市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院
• 专业治疗中心
• 学术和研究机构

全球CAR-T细胞疗法市场规模及复合年增长率（2026-2033年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Legend Biotech（USA）
• Allogene Therapeutics（USA）
• Cellectis（France）
• Precision BioSciences（USA）
• Arcellx（USA）
• Autolus Therapeutics（UK）
• Immatics NV（Germany）
• Caribou Biosciences（USA）
• Tessa Therapeutics（Singapore）
• Sorrento Therapeutics（USA）
• Precigen, Inc.（USA）
• SinoCellTech（China）
• Celyad Oncology（Belgium）
• Instil Bio（USA）
• Poseida Therapeutics（USA）
• Nkarta, Inc.（USA）
• Tmunity Therapeutics（USA）
• Innovative Cellular Therapeutics（China）
• Miltenyi Biotec（Germany）
• Prescient Therapeutics（Australia）

结论与建议

Global CAR T-Cell Therapy Market size was valued at USD 5 Billion in 2024 and is poised to grow from USD 6.91 Billion in 2025 to USD 92 Billion by 2033, growing at a CAGR of 38.2% during the forecast period (2026-2033).

The CAR T-Cell Therapy market is experiencing significant growth, driven by its transformative potential in treating hematological malignancies and the increasing global cancer prevalence alongside a demand for personalized therapies. Innovations in gene-editing technologies and substantial investments from major pharmaceutical companies have further propelled the development of advanced CAR T-cell therapies, supported by favorable regulatory environments. Notable efficacy in approved therapies has reinforced confidence among stakeholders and expanded patient access, particularly in countries with advancing healthcare systems. Nevertheless, challenges such as exorbitant treatment costs, complex manufacturing processes, and associated adverse events limit accessibility and market penetration. Additionally, a shortage of skilled professionals and inadequate infrastructure in emerging economies poses barriers to leveraging the full therapeutic potential of CAR T-cell therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global CAR T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global CAR T-Cell Therapy Market Segments Analysis

Global CAR T-Cell Therapy Market is segmented by Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User and region. Based on Product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi and Other Products. Based on Target, the market is segmented into CD19, BCMA, HER2 and Other Targets. Based on Indication, the market is segmented into Multiple Myeloma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia and Other Indications. Based on Therapy Type, the market is segmented into Monotherapy and Combination therapy. Based on Demographic, the market is segmented into Adults and Pediatrics. Based on Administration Type, the market is segmented into Inpatient and Outpatient. Based on End User, the market is segmented into Hospitals, Specialty Centers and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global CAR T-Cell Therapy Market

The Global CAR T-Cell Therapy market is poised for significant growth, largely fueled by the rising interest in personalized medicine. As more patients seek tailored treatment options, the demand for CAR T-cell therapy is expected to increase substantially. This innovative therapy's effectiveness can be enhanced through personalized approaches, which align treatment more closely with individual patient profiles. Such customization not only improves patient outcomes but also drives interest among healthcare professionals and organizations. As personalized medicine continues to take center stage in therapeutic developments, the CAR T-cell therapy market is likely to benefit immensely from this shift in focus towards individualized treatment strategies.

Restraints in the Global CAR T-Cell Therapy Market

The global CAR T-cell therapy market faces significant challenges related to the innovative nature of this treatment approach. Despite extensive testing, concerns about potential side effects and long-term safety remain prominent. These uncertainties are likely to limit the widespread acceptance and utilization of CAR T-cell therapy among healthcare providers and patients. As stakeholders in the market weigh the benefits against these risks, the hesitation to fully embrace this groundbreaking therapy could hinder its growth and integration into standard treatment protocols, impacting overall market development in the foreseeable future.

Market Trends of the Global CAR T-Cell Therapy Market

The Global CAR T-Cell Therapy market is witnessing a significant trend towards the development of allogeneic CAR T-cell therapies, which promise to streamline the manufacturing process by eliminating the need for patient-specific customization. This innovation is expected to enhance the accessibility and affordability of CAR T-cell treatments, broadening their market appeal. As companies focus on developing these therapies, they aim to not only improve patient outcomes but also position themselves favorably in emerging markets. This strategic shift will likely bolster growth opportunities within the sector, allowing providers to expand their business scope while catering to a diverse patient population.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global CAR T-Cell Therapy Market Size by Product & CAGR (2026-2033)

• Market Overview
• Yescarta
• Kymriah
• Carvykti
• Abecma
• Tecartus
• Breyanzi
• Other Products

Global CAR T-Cell Therapy Market Size by Target & CAGR (2026-2033)

• Market Overview
• CD19
• BCMA
• HER2
• Other Targets

Global CAR T-Cell Therapy Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Multiple Myeloma
• B-Cell Lymphoma
• Acute Lymphoblastic Leukemia
• Other Indications

Global CAR T-Cell Therapy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Monotherapy
• Combination therapy

Global CAR T-Cell Therapy Market Size by Demographic & CAGR (2026-2033)

• Market Overview
• Adults
• Pediatrics

Global CAR T-Cell Therapy Market Size by Administration Type & CAGR (2026-2033)

• Market Overview
• Inpatient
• Outpatient

Global CAR T-Cell Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Centers
• Academic & Research Institutes

Global CAR T-Cell Therapy Market Size & CAGR (2026-2033)

• North America (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • US
  • Canada
• Europe (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Legend Biotech (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcellx (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immatics N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tessa Therapeutics (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precigen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SinoCellTech (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celyad Oncology (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instil Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poseida Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nkarta, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tmunity Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovative Cellular Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Miltenyi Biotec (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prescient Therapeutics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations